Medical control of secondary hyperparathyroidism: We're not there yet

Vpu and BST2: Still Not There Yet?

Extensive investigations have identified two cellular proteins in humans that potently inhibit HIV type 1 (HIV-1) replication and are widely accepted as "restriction factors." APOBEC3G was identified as a restriction factor that diminishes HIV-1 replication by inducing G-to-A hypermutation in the viral genome, while BST2 has been identified as another restriction factor that impairs the release...

Parathyroidectomy in secondary hyperparathyroidism: Is there an optimal operative management?

BACKGROUND Subtotal parathyroidectomy (SPTX) and total PTX with autotransplantation (TPTX + AT) are both accepted operations for secondary hyperparathyroidism (2HPT). Studies have shown the 2 procedures to have similar rates of recurrent or persistent HPT (0% to 10%). The majority of these reports are small case series and despite apparently similar outcomes; the optimal operative management fo...

Medical management of secondary hyperparathyroidism in chronic renal failure.

Abnormalities in calcium and phosphorus metabolism are common, and metabolic bone disease develops often in patients with chronic renal failure (CRF). Effective clinical management includes measures to control phosphorus retention and prevent hyperphosphataemia, to maintain serum calcium concentrations within the normal range and to prevent excess parathyroid hormone (PTH) secretion by the judi...

Intensification of Anemia by Secondary Hyperparathyroidism in Hemodialysis Patients

The excessive amounts of parathyroid hormone in secondary hyperparathyroidism (SHPTH) is suggested to interfere with normal erythropoiesis.  In SHPTH, during chronic renal failure, due to the impairment of erythropoietin synthesis, this effect is more pronounced.  In the present study the role of secondary hyperparathyroidism in the severity of anemia was evaluated in hemodialysis patients (n=3...

Closer but not there yet: models in child injury research.